Skip to main content
OpenTrials
Completed

NCT Number: NCT02739880

Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule

The main objective of this study is to measure changes in the thickness of the vaginal lining (epithelium + underlying stroma) between 0 and 8 weeks after injection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–69 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France

Loading trial locations.

About this study

The secondary objectives of this study are to measure changes in the following between 0 and 8 weeks after injection:

A. vaginal flora and Nugent score.

B. vaginal pH.

C. functional evolution via the VHI index by Gloria Bachman (state of the vaginal mucosa), pain / dyspareunia (visual analog scale) and the satisfaction concerning care viay the PGI-I questionnaire (Patient Global Impression and Improvement).

D. Procollagen I and III gene expression (by PCR) and mitotic activity of the mucosa (Ki67 proliferation marker) based on biopsies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must have given her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 8 weeks of follow-up
  • The patient is menopausal (amenorrhea) for over 2 years and less than 10 years
  • The patient has a body mass index <35
  • The patient has sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.

Exclusion criteria

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant or breastfeeding
  • The patient is not menopausal (both clinically and biologically)
  • The patient has a body mass index > 35
  • The patient has a genital prolapse higher than stage 2 with a surgical indication
  • The patient has stress incontinence with a surgical indication
  • The patient suffers from vaginismus
  • Presence of an untreated viral, fungal or bacterial vulvovaginal or urinary infection
  • Hemorrhagic or neoplastic genital pathologies
  • Existence of a hormone-dependent tumor, genital bleeding of unknown origin
  • Current treatments based on antihypertensives, steroid anti-inflammatory drugs, anticoagulants, major antidepressants, aspirin
  • Known hypersensitivity to hyaluronic acid or mannitol
  • Known hypersensitivity to Betadine
  • Known hypersensitivity to Lidocaine
  • Hypersensitivity to EMLA®
  • Previous urogynaecological vulvovaginal surgery

Treatment and study plan

DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)

Device

Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule

The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G "spot or area of Gräfenberg ".

Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total.

Other names: Cross-linked Hyaluronic Acid, DESIRIAL®

Primary outcomes

  1. The thickness of the vaginal mucosa on a histological section

    Time frame: Day 0

  2. The thickness of the vaginal mucosa on a histological section

    Time frame: Week 8

Secondary outcomes

  1. Vaginal pH

    Time frame: Day 0

  2. Vaginal pH

    Time frame: Week 8

  3. Vaginal flora (on Pap smear)

    Time frame: Day 0

  4. Vaginal flora (on Pap smear)

    Time frame: Week 8

  5. Nugent score (on Pap smear)

    Time frame: Day 0

  6. Nugent score (on Pap smear)

    Time frame: Week 8

  7. PGI-I (Patient Global Impression and Improvement) Questionnaire

    Time frame: Week 8

  8. The Vaginal Health Index by Gloria Bachman

    Time frame: Day 0

  9. The Vaginal Health Index by Gloria Bachman

    Time frame: Week 8

  10. Pain (dyspareunia) by visual analog scale

    Time frame: Day 0

  11. Pain (dyspareunia) by visual analog scale

    Time frame: Week 8

  12. Measurement of collagen expression (procollagen I and III)

    Time frame: Day 0

  13. Measurement of collagen expression (procollagen I and III)

    Time frame: Week 8

  14. Level of Ki67 proliferation marker

    Time frame: Day 0

  15. Level of Ki67 proliferation marker

    Time frame: Week 8

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Collaborators

  • Laboratoires Vivacy

Registry information

Official study title

Evaluation of the Effect of Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule: A Prospective, Bicentric, Pilot Study

Acronym: INREG 1

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Apr 15, 2016
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.